首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2312篇
  免费   145篇
  国内免费   69篇
耳鼻咽喉   6篇
儿科学   28篇
妇产科学   9篇
基础医学   384篇
口腔科学   38篇
临床医学   212篇
内科学   251篇
皮肤病学   107篇
神经病学   78篇
特种医学   38篇
外科学   123篇
综合类   199篇
预防医学   82篇
眼科学   19篇
药学   801篇
中国医学   109篇
肿瘤学   42篇
  2023年   29篇
  2022年   52篇
  2021年   74篇
  2020年   55篇
  2019年   73篇
  2018年   93篇
  2017年   92篇
  2016年   62篇
  2015年   66篇
  2014年   137篇
  2013年   268篇
  2012年   113篇
  2011年   166篇
  2010年   110篇
  2009年   83篇
  2008年   94篇
  2007年   95篇
  2006年   65篇
  2005年   76篇
  2004年   65篇
  2003年   68篇
  2002年   56篇
  2001年   43篇
  2000年   28篇
  1999年   39篇
  1998年   26篇
  1997年   23篇
  1996年   20篇
  1995年   37篇
  1994年   26篇
  1993年   16篇
  1992年   17篇
  1991年   15篇
  1990年   16篇
  1989年   21篇
  1988年   8篇
  1987年   10篇
  1986年   14篇
  1985年   29篇
  1984年   33篇
  1983年   21篇
  1982年   19篇
  1981年   17篇
  1980年   12篇
  1979年   8篇
  1978年   8篇
  1977年   8篇
  1976年   9篇
  1975年   6篇
  1974年   2篇
排序方式: 共有2526条查询结果,搜索用时 15 毫秒
1.
PurposeTo investigate the safety and efficacy of an aqueous polyethylene glycol-based liquid embolic agent, Embrace Hydrogel Embolic System (HES), in the treatment of benign and malignant hypervascular tumors.Materials and MethodsA prospective, single-arm, multicenter study included 8 patients, 5 males and 3 females, with a median age of 58.5 years (30–85 years), who underwent embolization in 8 tumors between October 2019 and May 2020. Technical success was defined as successful delivery of HES to the index vessel, with disappearance of >90% of the targeted vascular enhancement or, for portal vein embolization, occlusion of the portal branches to the liver segments for future resection. The volume of HES administered, ease of use (5 point Likert scale), administration time, and adverse events (AEs) were recorded. Evaluation was performed at 7, 30, and 90 days via clinical assessment and blood testing, and follow-up imaging was performed at 30 days.ResultsEight patients were enrolled, and 10 embolizations were performed in 8 lesions. Tumors included hepatocellular carcinoma (n = 4), renal angiomyolipoma (n = 3), and intrahepatic cholangiocarcinoma (n = 1). Technical success was 100%, and the average ease of use was 3.3 ± 1.0 SD. The HES delivery time was 1–28 minutes (median, 16.5 minutes), and the HES volume injected was 0.4–4.0 mL (median, 1.3 mL). All patients reached 30-day follow-up with imaging, and 6 patients reached 90-day follow-up. There were 3 serious AEs in 2 patients that were unrelated to the embolic agent.ConclusionHES resulted in a 100% embolization technical success rate. The product ease of use was acceptable, and no target vessel recanalization was noted on follow-up imaging at 30 days.  相似文献   
2.
This study aimed at evaluating how encapsulation in a regular nanocarrier (NC) (providing extended circulation time) or in a brain-targeting NC (providing prolonged circulation time and increased brain uptake) may influence the therapeutic index compared with the unformulated drug and to explore the key parameters affecting therapeutic performance using a model-based approach. Pharmacokinetic (PK) models were built with chosen PK parameters. For a scenario where central effect depends on area under the unbound brain concentration curve and peripheral toxicity relates to peak unbound plasma concentration, dose-effect and drug-side effect curves were constructed, and the therapeutic index was evaluated. Regular NC improved the therapeutic index compared with the unformulated drug due to reduced peripheral toxicity, while brain-targeting NC enhanced the therapeutic index by lowering peripheral toxicity and increasing central effect. Decreasing drug release rate or systemic clearance of NC with drug still encapsulated could increase the therapeutic index. Also, a drug with shorter half-life would therapeutically benefit more from a NC encapsulation. This work provides insights into how a NC for brain delivery should be optimized to maximize the therapeutic performance and is helpful to predict if and to what extent a drug with certain PK properties would obtain therapeutic benefit from nanoencapsulation.  相似文献   
3.
Dimethyl isosorbide (DMI), which is currently under investigation for its potential use as a pharmaceutical vehicle and drug permeation enhancer, is a water-miscible liquid with relatively low viscosity. The solubilization behavior of DMI as a cosolvent for nonpolar drugs was characterized via dielectric constant measurements of binary solvent systems containing DMI and either water, propylene glycol (PG), or polyethylene glycol (PEG). Evidence from the dielectric constant profiles and NMR studies suggest that DMI undergoes complexation with water and PG, but not with PEG, through hydrogen bonding interactions. The solvent complexation exhibited a major effect on the solubilities of prednisone, dexamethasone, and prednisolone in the mixed solvent systems. Maximum solubility of each drug was found to occur near a DMI/water or DMI/PG concentration ratio of 1:2. In the DMI–PEG mixed system, while there is no apparent interaction between DMI and PEG molecules, the solubility of prednisone was found to increase with decreasing dielectric constant.  相似文献   
4.
采用正交试验优选出最佳条件为:当乙酰乙酸乙酯为0.2moL时,硫酸铁铵0.7g,环乙烷10mL。乙酰乙酸乙酯和惭二醇摩尔比为1:1.5,反应时间为5h。所得产率为59.2%。  相似文献   
5.
讨论了一系列N-酰化壳聚糖膜的抗张强度、透水性、VB_(12)的透过性、透氧性以及血液相容性。N-已酰化壳聚糖膜具有良好的血液相容性。在制膜过程中,加入分子量为1500的聚乙二醇为致孔剂,则可使N-己酰化壳聚糖膜的渗透性有较大提高。同时保持较好的血液相容性和强度。  相似文献   
6.
Dystonia is a common movement disorder which is thought to represent a disease of the basal ganglia. However, the pathogenesis of the idiopathic dystonias, i.e. the neuroanatomic and neurochemical basis, is still a mystery. Research in dystonia is complicated by the existence of various phenotypic and genotypic subtypes of idiopathic dystonia, probably related to heterogeneous dysfunctions.In neurological diseases in which no obvious neuronal degeneration can be found, such as in idiopathic dystonia, the identification of a primary defect is difficult, because of the large number of chemically distinct, but functionally interrelated, neurotransmitter systems in the brain.The variable response to pharmacological agents in patients with idiopathic dystonia supports the notion that the underlying biochemical dysfunctions vary in the subtypes of idiopathic dystonia. Hence, in basic research it is important to clearly define the involved type of dystonia.Animal models of dystonias were described as limited. However, over the last years, there has been considerable progress in the evaluation of animal models for different types of dystonia.Apart from animal models of symptomatic dystonia, genetic animal models with inherited dystonia which occurs in the absence of pathomorphological alterations in brain and spinal cord are described.This review will focus mainly on genetic animal models of different idiopathic dystonias and pathophysiological findings. In particular, in the case of the mutant dystonic (dt) rat, a model of generalized dystonia, and in the case of the genetically dystonic hamster (dtsz), a model of paroxysmal dystonic choreoathetosis has been used, as these show great promise in contributing to the identification of underlying mechanisms in idiopathic dystonias, although even a proper animal model will probably never be equivalent to a human disease.Several pathophysiological findings from animal models are in line with clinical observations in dystonic patients, indicating abnormalities not only in the basal ganglia and thalamic nuclei, but also in the cerebellum and brainstem. Through clinical studies and neurochemical data several similarities were found in the genetic animal models, although the current data indicates different defects in dystonic animals which is consistent with the notion that dystonia is a heterogenous disorder.Different supraspinal dysfunctions appear to lead to manifestation of dystonic movements and postures. In addition to increasing our understanding of the pathophysiology of idiopathic dystonia, animal models may help to improve therapeutic strategies for this movement disorder.  相似文献   
7.
We have examined 6 construction workers who developed chronic skin diseases on their hands over a period of 15 years (1970–1985). 4 developed a Trichophyton rubrum infection, and the other 2 an irritant contact dermatitis. All of them carried out jobs which caused traumatization of the skin, due to the presence of ethylene glycol and mineral oils during operation of pneumatic hammers in winter. They also suffered other types of skin trauma during their work. Construction workers may be at risk of developing an occupational skin disease involving fungal infection.  相似文献   
8.
The mechanism responsible for the decreased red blood cell (RBC) lifespan associated with feeding propylene glycol (PG)-containing diets was investigated to understand better how Heinz body-contained RBC are destroyed. Three cats were fed a diet containing 12% PG for 14 days and three other cats served as control. The experimental group developed reticulocytosis and increased Heinz body numbers. Red blood cell membrane immunoglobulih G (IgG) concentration and phagocytosis of RBC by peritoneal macrophages were lower in the PG group compared to the control group suggesting that neither IgG nor non-IgG-mediated phagocytosis was responsible for the RBC destruction. Osmotic fragility, rate of RBC proteolysis and mild mechanical fragility test results were not statistically different from controls. However, when RBC from cats fed PG were exposed to severe mechanical stress, their fragility were increased 2.2–2.8 times. Additionally, haptoglobin concentrations were decreased in the PG group. These data suggest that intravascular lysis may be involved in the pathogenesis of PG-induced RBC destruction.  相似文献   
9.
促渗剂对水合胼胝类脂热转变影响的差示扫描热分析研究   总被引:8,自引:0,他引:8  
从人胼胝组织提取出类脂经水合后代替人皮肤角质层用作差示扫描热分析研究促渗剂作用的简单模型。研究了1,8-桉油精,月桂氮酮和丙二醇等促渗剂对水合胼胝类脂热转变特征的影响。三种促渗剂均不同程度地降低水合胼胝类脂的热变温度,作用强弱依次为1,8-桉油精>月桂氮酮>丙二醇。丙二醇与1,8-桉油精或月桂氮酮混合应用时对热转变的影响具有协同作用。结果提示促渗剂可能改变脂质分子的排列和增加其流动性。同时,水的存在对脂质分子物理结构的形成具有重要作用。  相似文献   
10.
单甲氧聚乙二醇化学修饰药物酶的研究进展   总被引:4,自引:0,他引:4  
用单甲氧基聚乙二醉(1)化学修饰药物酶是生化药物研究开发的重要手段之一。本文综述了1化学修饰药物酶的一般方法及修饰后酶在生物和理化性质方面的变化,同时对1研究前景进行展望,并指出了尚待解决的问题。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号